STOCK TITAN

Scinai sets ADS change equal to 1-for-4 reverse split

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. (SCNI) announced that, effective November 19, 2026, its ADS ratio will change from one ADS representing 40,000 ordinary shares to one ADS representing 160,000 ordinary shares. For ADS holders, the change has the same effect as a one-for-four reverse split. ADSs are expected to begin trading on an adjusted basis at the opening of trading that day on the Nasdaq Capital Market under the symbol SCNI.

The company says the change is intended to increase the per-ADS trading price and regain compliance with Nasdaq’s $1.00 minimum bid price requirement; there is no assurance it will regain or maintain compliance. Holders need take no action. Fractional entitlements will be aggregated, and the depositary bank will attempt to sell them and distribute the net cash proceeds to applicable holders.

Current ADS ratio 1 ADS per 40,000 ordinary shares Ratio before the change effective November 19, 2026
New ADS ratio 1 ADS per 160,000 ordinary shares Effective November 19, 2026
ADS reverse split 1-for-4 Effect of the ratio change for ADS holders
Nasdaq minimum bid price $1.00 per ADS Continued-listing requirement under Nasdaq Listing Rule 5550(a)(2)
American Depositary Shares technical
"American Depositary Shares (“ADSs”)"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
one-for-four reverse split technical
"same effect as a one-for-four reverse split of the ADSs"
Nasdaq Listing Rule 5550(a)(2) regulatory
"Nasdaq Listing Rule 5550(a)(2)"
minimum bid price regulatory
"requires a minimum bid price of $1.00 per ADS"
The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.
fractional entitlements technical
"fractional entitlements to new ADSs will be aggregated"
Fractional entitlements occur when a corporate action (like a dividend, stock split, rights offering or consolidation) would give a shareholder a non-whole share or security — for example, 0.5 of a share. Companies typically settle these fractions by paying a small cash amount or rounding up/down, and this matters to investors because it changes cash balances, can slightly alter ownership percentages, and may have small tax and record-keeping implications, much like receiving change after splitting a bill.
Split Ratio 1-for-4 reverse split
Effective Date November 19, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the SCNI ADS ratio change?

SCNI’s ADS ratio will change from one ADS representing 40,000 ordinary shares to one ADS representing 160,000 ordinary shares, an effect equivalent for ADS holders to a one-for-four reverse split.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of November 2026

 

Commission File Number: 001-37353

 

SCINAI IMMUNOTHERAPEUTICS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

ADS Ratio Change

 

On November 17, 2026, Scinai Immunotherapeutics Ltd. (the “Company”) announced that, effective November 19, 2026, the ratio of its American Depositary Shares (“ADSs”) to its non-traded ordinary shares will change from the current ratio of one (1) ADS representing forty thousand (40,000) ordinary shares to a new ratio of one (1) ADS representing one hundred sixty thousand (160,000) ordinary shares (the “ADS Ratio Change”).

 

For holders of the Company’s ADSs, the ADS Ratio Change will have the same effect as a one-for-four reverse split of the ADSs.

 

The Company’s ADSs are expected to begin trading on the Nasdaq Capital Market on an adjusted basis at the opening of trading on November 19, 2026 and will continue to trade under the symbol “SCNI.” The new CUSIP number for the ADSs will be 09073Q501.

 

No action is required by the holders of the ADSs to affect the ADS Ratio Change, and no fractional new ADSs will be issued in connection with the change in ADS Ratio Change. Instead, fractional entitlements to new ADSs will be aggregated and the depositary bank will attempt to sell them with the net cash proceeds from the sale of the fractional ADS entitlements to be distributed to the applicable ADS holders by the depositary bank.

 

The Company is implementing the ADS Ratio Change with the objective of increasing the per-ADS trading price and regaining compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS for continued listing on the Nasdaq Capital Market. There can be no assurance that the ADS Ratio Change will enable the Company to regain or maintain compliance with Nasdaq’s continued-listing requirements.

 

This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-291460, 333-271293 and 333-239344) and Form F-3 (File Nos. 333-299674, 333-295698 and 333-276767), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Scinai Immunotherapeutics Ltd.
     
Date: November 17, 2026 By: /s/ Amir Reichman
    Amir Reichman
    Chief Executive Officer

 

2

 

Keep reading